// App-Quantinova.ai

8021 : Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).

Researchers

Presenter

  • Andrzej J. Jakubowiak

Principal Investigators

  • Agnes Benedict

  • Sumeet Panjabi

  • Ivan Houisse

  • Marco Campioni

  • Andromachi Giannopoulou

  • Sanjay Aggarwal

  • Rafael Fonseca

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • Evidera Inc., Budapest, Hungary

  • Amgen Inc, South San Francisco, CA

  • Amgen Inc., Zug, Switzerland

  • Amgen Inc, Thousand Oaks, CA

  • Mayo Clinic, Scottsdale, AZ

Locations

  • United States

  • Switzerland

  • Hungary

Companies

  • Evidera, Inc.

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • carfilzomib Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved